Aprepitant
DrugOther names: MK0869
NCT Number: NCT00035282
A clinical study to determine the efficacy and safety of an investigational medication (MK0869) in the treatment of depression.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 3
The duration of treatment is 8 weeks.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Patients with Major Depressive Disorder
Other names: MK0869
Time frame: at week 8
Time frame: at week 8
Merck Sharp & Dohme LLC
Industry
A Double-Blind, Placebo- and Active-Controlled Acute and Extension Study of MK0869 in the Treatment of Patients With Major Depressive Disorder
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04276259
Behavior, Behavioral Symptoms
Pittsburgh, Pennsylvania, United States
View Trial DetailsNCT06001346
Behavior, Behavioral Symptoms
Ames, Iowa, United States
View Trial DetailsNCT06266390
Behavior, Behavioral Symptoms
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT06267846
Behavior, Behavioral Symptoms
Little Rock, Arkansas, United States
View Trial Details